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Background and Aims 
Minimally invasive treatments of anastomotic benign biliary stricture (BBS) after orthotopic 
liver transplantation (OLT) include endoscopic placement of multiple plastic stents or fully 
covered self-expandable metal stents (FCSEMSs). No multi-year efficacy data are available on 
FCSEMS treatment after OLT. 
 
Methods 
We prospectively studied long-term efficacy and safety of FCSEMS treatment in adults 18 years 
and older with past OLT, cholangiographically confirmed BBS, and an indication for ERCP with 
stent placement. Stent removal was planned after 4 to 6 months, with subsequent follow-up until 
5 years or stricture recurrence. Long-term outcomes were freedom from stricture recurrence, 
freedom from recurrent stent placement, and stent-rela ed serious adverse events (SAEs). 
 
Results 
In 41 patients, long-term follow-up began after FCSEMS removal (n=33) or observation of 
complete distal migration (CDM) (n=8). On an intentio -to-treat basis, the 5-year probability of 
remaining stent-free after FCSEMS removal or observation of CDM was 48.9% (95% CI, 
33.2%−64.7%) among all patients and 60.9% (95% CI, 43.6%−78.2%) among 31 patients with 
over 4 months of FCSEMS indwell time. In 28 patients with stricture resolution at FCSEMS 
removal or observed CDM (median 5.0 months indwell time), the 5-year probability of no 
stricture recurrence was 72.6% (95% CI, 55.3%−90%). Sixteen (39%) patients had at least 1 





By 5 years after temporary FCSEMS treatment of post-OLT BBS, approximately half of all 
patients remained stent-free on an intention-to-treat basis. Stent-related SAEs (especially 
cholangitis) were common. FCSEMS placement is a viable long-term treatment option for 
patients with post-OLT BBS. 
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BACKGROUND AND AIMS 
Approximately 6% to 12% of patients who undergo liver transplantation subsequently develop 
an anastomotic biliary stricture.1 Anastomotic strictures in the early posttransplant period may be 
attributed to, among other factors, scarring, donor-recipient bile duct mismatch, edema of the 
healing anastomosis, peritransplant infection, anastomotic leaks, and possibly to surgical 
technique.2 Late anastomotic stricture tends to result from fibrotic healing due to ischemia at the 
end of the donor or recipient bile duct.2 Even though most clinicians assume early strictures a  
associated with a better prognosis and generally do not need intensive treatment, the literature on 




Symptomatic anastomotic strictures warrant clinical ntervention because biliary obstruction can 
lead to jaundice, cholangitis, common bile duct stones and potentially biliary cirrhosis in chronic 
cases.5 Endoscopic management is the first-line treatment for anastomotic strictures after 
orthotopic liver transplantation (OLT).4 Multiple plastic stents (MPSs) or fully covered self-
expandable metal stents (FCSEMSs) as endoscopic treatment options have been studied in 
randomized controlled trials (RCTs).6,7 Progressive plastic stent placement of anastomotic 
strictures after OLT is highly efficacious and saves 80% of patients from undergoing 
complicated surgical repair or even retransplantation; however, the protocol is demanding and 
burdensome, necessitating 4 or more ERCP procedures with adverse events occurring in 1 out of 
5 procedures.8 Although FCSEMSs has the advantage of fewer anticipated stent exchanges, a 
2013 systematic review9 and two 2017 meta-analyses10,11 of observational data did not suggest a 
clear overall advantage of SEMS use over MPSs for biliary anastomotic stricture after OLT. A 
2019 meta-analysis12 including 4 RCTs concluded that FCSEMSs and MPSs had equal 
anastomotic biliary stricture resolution and recurrence and similar overall rates of adverse events 
or stent migration. A trend towards a higher stricture recurrence rate in FCSEMS disappeared 
when trials with shorter stent indwell time were excluded.12 Anastomotic stricture resolution 
rates are higher for liver transplant patients treated with more than 12 months of stent placement 
and a higher total number of stents.4 Accordingly, a 2018 meta-analysis of 4 RCTs of metallic 
versus plastic stents to treat biliary stricture aft r OLT mentioned the importance of long-term 
follow-up to support evidence-based conclusions regarding stricture recurrence in these patients, 
stating that “a follow-up of 12 months is probably not enough to make firm assumptions on long-
term efficacy (especially in the FCSEMS group because more is known about the chance of 




To estimate long-term efficacy and safety of FCSEMS in this patient population, we studied 41 
patients with a history of OLT who participated in a prospective cohort study of FCSEMS to 
treat anastomotic biliary stricture.14 Participants were followed up to 5 years after FCSEM  
removal or after observation of complete distal stent migration (CDM) to assess maintenance of 
stricture resolution, rates of freedom from stent placement, and long-term safety. 
 
METHODS 
Study design  
This analysis is part of a multicenter, prospective, nonrandomized observational study 
(ClincialTrials.gov NCT01014390 and CTRI/2012/12/003166) of an FCSEMS to treat benign 
biliary stricture (BBS) including 187 total participants in 3 patient subgroups: patients with 
chronic pancreatitis, with a history of cholecystectomy, or with a history of OLT. Methods of the 
main study were documented previously.14 Patients from 8 of the 13 original study sites were 
represented in the current analysis. The Independent Ethics Committee at each study site 
approved the study protocol, and all study participants provided written informed consent. An 
Independent Medical Reviewer reviewed all stent- or stent-removal-related serious adverse 
events (SAEs), all reinterventions and all deaths. T e medical reviewer was a gastroenterologist 
experienced in treating biliary obstructions and performing interventional endoscopic 
procedures, and not employed by the study sponsor or by a clinical study site. The study was 




The FCSEMS studied was the fully covered WallFlex Biliary RX Stent (Boston Scientific 
Marlborough, Mass, USA), which is a U.S. Food and Drug Administration-approved for 
palliative and preoperative use in malignant biliary strictures and for indwell up to 12 months to 
treat benign biliary strictures secondary to chronic pancreatitis. The FCSEMS was placed at the 
baseline visit (Figure 1), after which patients had telephone or in-person assessments for 
symptoms of biliary obstruction (right upper quadrant pain, fever/chills, jaundice, itching, dark 
urine, pale stools, nausea/vomiting), adverse events, a d/or device malfunction at 1 week, 3 
months, or ad lib in response to concerning symptoms r adverse events. FCSEMS removal was 
planned at 4–6 months with the expectation that a shorter indwell time (compared with standard 
12-month indwell for plastic stents and FCSEMS for other indications) would prevent late 
adverse events in the immunosuppressed post-OLT patients.14 After stent removal, assessments 
were performed at 1, 3, 6, 12, 18, and 24 months, then annually up to 5 years. Patients were 
followed until 5 years after FCSEMS removal or until stricture recurrence (managed with new 
stent placement), whichever occurred earlier. 
 
Patient population 
Eligible patients were 18 years and older with cholangiographic confirmation of a bile duct 
stricture and an indication (eg, clinical symptoms, abnormal laboratory values with known bile 
duct stricture, planned exchange of plastic stents) for ERCP with stent placement to treat BBSs 
of the common bile duct. Patients with or without documented history of previous treatment with 
any number of plastic stents were eligible. Exclusion criteria included history of live liver donor 
transplantation, malignant biliary stricture, stricture location within 2 cm of bile duct bifurcation, 
prior biliary SEMSs, suspected stricture ischemia based on imaging of hepatic artery 
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Occlusion, or endoscopic evidence of biliary cast syndrome, bile duct perforation, known fistula, 
or symptomatic duodenal stenosis with gastric stasi. 
 
Stricture resolution and long-term endpoints 
Stricture resolution was established at the time of ndoscopic FCSEMS removal or observation 
of complete distal migration (CDM), and was defined by lack of need for recurrent stent 
placement at that time.  
 
The long-term efficacy endpoint was freedom from stricture recurrence defined by absence of  
recurrent stent placement during 5-year follow-up post-stent removal or observation of CDM. 
This was  assessed on an intention-to-treat basis during 5 years of follow-up after FCSEMS 
removal or observation of CDM for all patients, and i  the subset of patients observed to have 
stricture resolution at the time of FCSEMS removal or observation of CDM. 
 
The safety endpoints were (1) SAEs related to the stent or to stent removal or (2) any SAEs 
occurring within 30 days before stricture recurrence. An SAE was defined as an event that led to 
death, serious deterioration in the health (life-threatening illness or injury, permanent impairment 
of bodily structure or function or medical/surgical intervention required to prevent such an 
impairment, or new or prolonged hospitalization), or fetal death, distress, or abnormality.  
 
Statistical analysis 
Baseline characteristics of the patients and their baseline endoscopic procedure were calculated, 
including mean, median, standard deviation (SD), interquartile range (IQR), and range for 
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continuous variables (age, time from transplant, serum total bilirubin, and alkaline phosphatase), 
and stratified incidence for categorical variables (sex, primary reason for transplant, stricture 
location, history of plastic stent placement, stricture location, and size of the FCSEMS placed). 
Freedom from stricture recurrence and freedom from recurrent stent placement were analyzed 
using Kaplan-Meier techniques, differences between those with and without migration were 
tested using the log-rank test. Univariate and multivariate analyses were used to determine 
whether baseline characteristics predicted outcomes. Specifically, logistic regression using a 
Firth bias adjustment was used for stricture resolution, and Cox proportional hazards models 
were performed for serious adverse events and freedom from stricture recurrence. Both were 
performed using the model building technique of stepwise regression, with P ≤ 0.10 for 
covariates to stay in the model and P > 0.10 to exit the model. The significance level for all 
analyses was set at 0.05. All analyses were performed using SAS version 9.4.    
 
RESULTS 
Baseline characteristics and endoscopic stent placement 
Of 42 patients enrolled, 1 could not be evaluated due to death from an infection that was 
unrelated to the study. This patient had not experienced any FCSEMS or FCSEMS placement 
related adverse event and had no signs of FCSEMS dysfunction at the time of death. Forty-one 
patients with a history of OLT were included in thecurrent analysis of 5-year outcomes after 
FCSEMS removal or after observation of CDM (Figure 2). The OLT cohort had a mean age of 
56.7 ± 11.5 years and was predominantly male (82.9%, 34/41) (Table 1). All patients had 
received transplants from cadaveric donors, with a me n time since transplant of 32.9 (range 0.1 
to 234.5) months. Alcoholic cirrhosis (39.0%, 16/41) and hepatitis B or C (26.8%, 11/41) were 
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the most common primary reasons for liver transplant; other documented reasons included 
cryptogenic cirrhosis (9.8%, 4/41), hepatocellular c ncer (7.3%, 3/41), primary biliary cirrhosis 
(4.9%, 2/41), primary sclerosing cholangitis (2.4%, 1/41) and autoimmune hepatitis (2.4%, 
1/41), acute liver failure (2.4%, 1/41), and other (4.9%, 2/41). Most (95.1%, 39/41) patients had 
a history of sphincterotomy, and almost half (48.8%, 20/41) had undergone prior plastic stent 
placement.  
 
At the baseline endoscopic examination, patients were found to have strictures located in the 
proximal (39.0%, 16/41) and mid (61.0%, 25/41) common bile duct. Plastic stents were removed 
from 14 (34.1%) patients, ranging from 1 stent (26.8%, 11/41) to 3-5 stents (2.4%, 1/41) before 
FCSEMS placement. FCSEMS placement was technically successful with satisfactory 
positioning in all patients. The most common size of study FCSEMS placed at the baseline visit 
was 10 mm x 80 mm in 32 (78.0%) patients (Table 1). 
 
Migration and stricture resolution assessed at time of stent removal 
Twenty-five (61.0%) patients underwent FCSEMS removal during the planned period of 4 to 6 
months (median indwell 153 days), 8 (19.5%) underwent r moval before 4 months (median 
indwell 22 days), and 8 (19.5%) were observed to have spontaneous CDM after an estimated 
median indwell of 167.5 days (Figure 1). Six patients had over 6 months of indwell time, 
including 5 with stent removal within 198 days (6.6 months), and 1 with removal at 355 days 
(11.8 months). Successful endoscopic removal of all 33 (100%) FCSEMS that had not 
completely migrated was achieved using forceps/graspers/snares (n=31) or a stent-in-stent 
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technique (n=2). The FCSEMS covering was observed to no  be compromised for any stent at 
the time of removal. 
 
Twenty-four (58.5%) patients were noted to have stent migration at the time of FCSEMS 
removal; of these, 8 were spontaneous CDM, 8 were pa tial distal migrations, and 8 were 
proximal migrations; within these groups, 4, 3, and 2 patients, respectively, were symptomatic at 
the time of FCSEMS removal and were restented with a plastic stent(s) immediately. A 
multivariate model suggested that “over 1 year since transplant” was associated with 
significantly lower risk (hazard ratio [HR], 0.4; 95% CI, 0.2−0.8; P=0.018), and “alcoholism as 
reason for transplant” was associated with higher risk (HR, 2.8; 95% CI, 1.2−6.4; P=0.013) of 
any stent migration. “Alcoholism as reason for transplant” was also associated with higher risk 
(HR, 5.7; 95% CI, 1.2−26.8; P=0.029) of proximal migration. 
 
Twenty-eight (68.3%; 95% CI, 51.9%−81.9%)  patients had either stricture resolution or 
observation of complete distal migration and did not require recurrent stent placement. 
Univariate/multivariate analyses did not reveal independent predictors for stricture resolution 
observed at the time of stent removal.  
 
Freedom from recurrent stent placement after stent removal  
Among all 41 patients, the probability of remaining free from recurrent stent placement by 5 
years after FCSEMS removal was 48.9% (95% CI, 33.2%−64.7%) (Figure 3A). Post hoc 
analyses showed that among 31 patients with an implanted stent for more than 4 months, the 
probability of remaining stent-free by 5 years after FCSEMS removal was 60.9%. In addition, 
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75.5% (95% CI, 54.5%−96.5%) of patients without migrations compared with 27.9% (95% CI, 
9.1%−46.8%) of patients with migrations remained stent-free by 5 years after FCSEMS removal 
(P = 0.004) (Figure 3B).  
 
Freedom from stricture recurrence in patients with stricture resolution at time of stent 
removal  
Among the 28 patients who had stricture resolution or observation of CDM at the time of 
FCSEMS removal (after median 151 days [5.0 months] indwell time), the probability of being 
without stricture recurrence by 5 years after stent r moval was 72.6% (95% CI, 55.3%−90%) 
(Figure 4).  
 
Seven (7) patients had stricture recurrence during follow-up, with median time to recurrence of 
3.4 (IQR, 1.8−6.6) months. All recurrent strictures were at the original location and occurred by 
15 (range 1.7–14.7) months after stent removal. All recurrent strictures were successfully 
managed with recurrent stent placement; no patients r quired reintervention with bypass surgery. 
Univariate/multivariate analysis did not reveal independent risk factors for stricture recurrence.  
 
Serious adverse events related to stent or stent removal 
Among all 41 participants, 16 (39%) had at least one FCSEMS- or FCSEMS-removal-related 
SAE, with cholangitis (n=10) and abdominal pain (n=4) being the most common (Table 2). 
Univariate and multivariate analyses showed that compared with those with transplantation less 
than 1 year before enrollment, patients with transplantation at least 1 year before enrollment had 
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a significantly lower risk of adverse events (HR, 0.3; 95% CI, 0.1 to 0.8) and cholangitis 
specifically (HR, 0.2; 95% CI, 0.1 to 0.7).  
 
Among the 7 patients who had stricture resolution after FCSEMS treatment and then experienced 
stricture recurrence during follow-up, 5 had cholangitis/fever and/or elevated liver function tests 
within 30 days before recurrence.  
 
DISCUSSION 
We studied the efficacy and safety of FCSEMSs to treat anastomotic stricture in patients with 
OLT followed for up to 5 years after FCSEMS removal. On an intention-to-treat basis, the 
probability of remaining stent-free was 49% for all patients and 61% for those with a stent 
indwelling for the full intended 4 to 6 months. Among patients with stricture resolution at the 
time of FCSEMS removal, the 5-year probability of being without stricture recurrence was 73%. 
All recurrent strictures were at the original location and occurred no later than 15 months after 
stent removal. Spontaneous complete distal migrations occurred in 20%, and SAEs related to the 
stent or stent removal occurred in 39% of participants. 
  
Since Costamagna et al15 described the technique in 2001, progressive dilation by insertion of 
increasing numbers of multiple plastic stents has been the most widely used endoscopic 
treatment for BBS. An average of 3 to 4 ERCP procedur s are required to dilate, deploy stents, 
up-size, and ultimately remove all stents once the s ricture has resolved,16 and the repeated 
endoscopic interventions may extend up to 24 months to achieve sustained clinical success.10 
FCSEMS treatment of BBS has been studied since 2009,17 and 4 randomized trials comparing 
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FCSEMS to multiple plastic stents to treat BBS in cohorts including post-OLT patients have 
been conducted since 2014.6,7,18,19 Prospective and retrospective cohort studies and romized 
trials focused on post-OLT patients have consistently reported FCSEMS to be noninferior to 
multiple plastic stents with respect to stricture resolution, stricture recurrence and overall adverse 
events,10-13 with one RCT reporting a higher stricture recurrence rate in the FCSEMS groups 
when the stents were removed early.7 A 2019 meta-analysis of data from 4 RCTs concluded that 
FCSEMS were associated with a reduced number of procedures and were a cost-sparing 
intervention overall.12 However, because only 205 patients were represented i  the RCTs and 
follow-up was as short as 1 year, experts have emphasized the need for further RCTs with larger 
sample size and longer follow up (eg, at least 2 years13) for more definitive findings. In our 
study, strictures recurred as late as 15 months after FCSEMS removal, which supports that 
follow-up of at least 2 years is important for a thorough evaluation of FCSEMS efficacy and 
safety.  
 
The overall 5-year stricture recurrence rate was 31.7% in our OLT cohort, which was similar 
to7,18 or higher than6,19 stricture recurrence rates in the FCSEMS arm of RCTs in OLT cohorts 
followed for 1 to 3 years on average. This rate washigher than the estimated 5-year rates of 
stricture recurrence reported for patients postcholecystectomy (15.4%)20 or with chronic 
pancreatitis (22.6%)21 in the original cohort.14 The higher rate was understandable considering 
multiple etiologies for biliary stricture in OLT patients including ischemia of the biliary tree 
from chronic rejection, or technical biliary advers events such as kinking or anastomotic leaks.22 
Multivariate analyses in our study did not identify independent predictors of 5-year stricture 
recurrence, but findings were limited by the small number of participants who could be followed 
for this endpoint. For example, prior studies have reported that liver transplantation patients with 
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more than 12 months of plastic stent placement for BBS are less likely to have stricture 
recurrence compared with those without prior stent placement.23 Of the 28 participants who were 
followed for 5-year stricture recurrence, 7 had strictu e recurrence, of whom 4 (51.7%) had prior 
plastic stent placement. A larger study population and details regarding the time period of prior 
stent placement would have allowed further investigation of this predictor.  
 
Stent- and stent-removal related SAEs occurred in 39% of these patients, primarily due to 
cholangitis (24.4%). This compares with overall SAE rates ranging from 10% (1/10) to 40.4% 
(23/57) in 3 RCTs of covered metallic stents versus pla tic stents for BBS that included OLT 
patients.6,7,18 Biliary adverse events as a whole are common in the OLT patient population, 
occurring in 10% to 30% after whole-organ OLT and resulting in mortality rates of up to 10% of 
cases.22 Age over 60 (seen in 18 [44%] of our participants at baseline) and primary sclerosing 
cholangitis as the transplant indication (1 participant) are known risk factors for biliary adverse 
events after liver transplantation.24 Immunosuppression was a predisposing factor to infections in 
this cohort, ie, OLT patients undergo intensive perioperative prophylactic immunosuppressive 
induction therapy to prevent acute cellular rejection in the first months after transplantation, 
followed by maintenance immunosuppressive therapy for life.25 Infection risk is lower with 
tapered immunosuppression by 12 months after transpl t; however, a Finnish registry study 
with 3923 person-years of follow-up estimated that after the first year posttransplant, 1 in 15 
liver transplant patients will have an episode of cholangitis or other severe infection each year.26 
Multivariate analyses in our study suggested that longer time since liver transplantation was 
associated with a lower risk of adverse events and of cholangitis specifically. Patients who 
develop BBS later in the posttransplant period might be expected to have a more benign course 
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after surviving the immediate postoperative period when the risks of postoperative adverse 
events or graft failure are the highest.2  
 
Our study had several limitations and considerations affecting interpretation. It was a small 
prospective study with limited power to estimate patient characteristics associated with the 
efficacy and safety endpoints, and with no plastic tent comparator. Patients with prior plastic 
stent placement were eligible for the study and comprised approximately half of the OLT cohort. 
This could have caused selection bias favoring either strictures that had failed earlier treatment 
and were more difficult to treat, or inclusion of more patients with a prior sphincterotomy (95% 
of our cohort) for whom stent migration might have been more likely compared with patients 
with a native papilla.7 Because of the small study size, some findings regarding risk factors (eg, 
association between alcoholism as reason for transpl t and stent migration) might have been 
spurious. The study was not designed to compare FCSEMS with multiple plastic stent placement 
or variants27 that have also shown good efficacy. Some authors are employees of the sponsor of 
the study, some investigators were paid consultants for or have received research funding from 
the study sponsor, and some have received funding from another manufacturer of FCSEMS. This 
might have influenced their willingness to participate in the study but would not change their 
ability to objectively collect data. 
 
In OLT patients with anastomotic biliary stricture t ated with FCSEMS, the probability of 
remaining stent-free by 5 years was approximately 50% for all patients, and over 70% for those 
with stricture resolution after a median 5.0 months of FCSEMS indwell time. All stricture 
recurrences occurred by 15 months after stent removal. FCSEMS continues to show good 
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efficacy and an acceptable level of safety for OLT patients who have post-OLT biliary stricture 
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Figure 1. A, Cholangiogram showing an anastomotic s tricture after orthotopic liver 
transplant treated by (B) placement of fully covere d self-expanding metal stent. C, The 
stricture is resolved after stent removal. Visible coils were placed during 
radioembolization before transplantation. 
 
            
 Figure 2. Flowchart of patients with a history of o rthotopic liver transplant and benign 
biliary strictures treated with fully covered self- expanding metal stents.                 
Figure 3. A, Kaplan-Meier analysis of patients who remained free from recurrent stent 
placement (N=41) . The cumulative probability of remaining free from recurrent stent placement 
after removal of a fully covered self-expanding metal stent (FCSEMS) placement until 5 years 
after FCSEMS removal was estimated among all patients. Patients who died were treatment 
failures, or who were lost to follow-up between FCSEMS removal to 5 years’ follow-up were 
censored. Median follow-up time was 62.2 months after FCSEMS    . Median time to recurrent 
stent placement was 5.6 months after FCSEMS placement (range 0.2-19.4; interquartile range, 
0.7-7.7). 3, Kaplan-Meier analysis of patients who remained f ree from recurrent stent 
placement, by stent migration (N=41). The cumulative probability of remaining free from 
recurrent stent placement from removal of a fully covered self-expanding metal stent (FCSEMS) 
until 5 years later was significantly longer in patients with no stent migration compared with 
those with migration (75.5% vs 27.9% respectively, p=0.004). 
 
Figure 4. Kaplan-Meier analysis of freedom from str icture recurrence in patients with 
stricture resolution at the time of endoscopic FCSE MS removal or observation of 
complete distal migration  (n=28). The cumulative probability of being free from recurrent stent 
placement from the time of fully covered self-expanding metal stents (FCSEMSs) removal until 
5 years later in patients who had stricture resolution at removal (n=28) is presented. Patients 
who died or were lost to follow-up from the time of FCSEMS removal to 5-year follow-up were 
censored. The median follow-up time after FCSEMS removal was 57.3 months (interquartile 
range, 21.9-60.2) for 28 patients. The median time to stricture recurrence after FCSEMS 
removal was 3.4 months (interquartile range, 1.8-6.6) in 7 patients. 
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Characteristic  Mean ± SD (range) or % (n/N)  
Patients   
Age, mean years  56.7 ± 11.5 
(28.0,77.0) 
Male 82.9% (34/41) 
Primary reason for liver transplant  
Alcoholic cirrhosis 39.0% (16/41) 
Hepatitis B or C 26.8% (11/41) 
Other 34.1% (14/41) 
Time from transplant, months 32.9 ± 53.2 
(0.1,234.5) 
Total bilirubin level, mg/dL 4.5 ± 8.1 
(0.3,35.4) 
Alkaline phosphatase level, IU/L 332.6 ± 429.4 
(39.0,2282.0) 
Baseline procedure   
Stricture Location  
Mid 61.0% (25/41) 
Proximal 39.0% (16/41) 
Gallbladder in situ 0.0% (0/41) 
Sphincterotomized 95.1% (39/41) 
Prior plastic stent placement only 22.0% (9/41) 
Prior balloon dilation only 9.8% (4/41) 
Prior plastic stent placement and balloon dilation 17.1% (7/41) 
Plastic stents removed  
0 65.9% (27/41) 
1 26.8% (11/41) 
2 4.9% (2/41) 
3-5 2.4% (1/41) 
Study stent size  
8 x 80 mm 2.4% (1/41) 
10 x 60 mm 19.5% (8/41) 
10 x 80 mm 78.0% (32/41) 




Table 2. Stent or stent-removal-related serious adv erse events (SAEs) among all patients 
(N=41)  
 
SAE % (n/N patients)  
Cholangitis/fever 24.4% (10/41) 
Abdominal pain 9.8% (4/41) 
Cholestasis 2.4% (1/41) 
Self-limited bleeding in bile duct 2.4% (1/41) 
Elevated serum bilirubin 2.4% (1/41) 
Total patients with ≥1 SAE* 39.0% (16/41) 
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Acronyms and abbreviations 
 
 
BBS: benign biliary stricture  
 
CDM: complete distal migration  
 
CI: confidence interval 
 
ERCP: endoscopic retrograde cholangiopancreatography 
 
FCSEMS: fully covered self-expanding metal stent 
 
HR: hazard ratio 
 
IQR: inter-quartile range  
 
MPS: multiple plastic stents  
 
OLT: orthotopic liver transplantation  
 
RCT: randomized controlled trial 
 
SAE: serious adverse event 
 
SAS: Statistical Analysis System 
 
SD: standard deviation  
 
 
 
 
